These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6981054)

  • 1. Plasma phenylalanine: tyrosine ratios during high-dose methotrexate-citrovorum "rescue".
    Hilton MA; Patel CC; Bertolone SJ; Kmetz DR; Clark LW
    Med Pediatr Oncol; 1982; 10(4):389-95. PubMed ID: 6981054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily profiles of plasma phenylalanine and tyrosine in patients with osteogenic sarcoma during treatment with high-dose methotrexate-citrovorum rescue.
    Hilton MA; Bertolone S; Patel CC
    Med Pediatr Oncol; 1989; 17(4):265-70. PubMed ID: 2787470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor).
    Juergens H; Kosloff C; Nirenberg A; Mehta BM; Huvos AG; Rosen G
    Natl Cancer Inst Monogr; 1981 Apr; (56):221-6. PubMed ID: 6975439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate clearance and clinical toxicity in osteosarcoma following high-dose methotrexate therapy.
    Iqbal MP; Khursheed M; Mahboobali N
    J Pak Med Assoc; 1989 Feb; 39(2):38-42. PubMed ID: 2499702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
    Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
    Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
    Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
    Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
    Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
    Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
    Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
    Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
    Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selected applications of methotrexate alone and in combination in osteosarcoma.
    Pratt CB
    Cancer Treat Rep; 1981; 65 Suppl 1():107-11. PubMed ID: 6976828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose leucovorin as sole therapy for methotrexate toxicity.
    Flombaum CD; Meyers PA
    J Clin Oncol; 1999 May; 17(5):1589-94. PubMed ID: 10334548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
    Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
    Perez C; Wang YM; Sutow WW; Herson J
    Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.
    Rosen G; Suwansirikul S; Kwon C; Tan C; Wu SJ; Beattie EJ; Murphy ML
    Cancer; 1974 Apr; 33(4):1151-63. PubMed ID: 4544836
    [No Abstract]   [Full Text] [Related]  

  • 15. The safety of administration of massive doses of methotrexate (50 g) with equimolar citrovorum factor rescue in adult patients.
    Reggev A; Djerassi I
    Cancer; 1988 Jun; 61(12):2423-8. PubMed ID: 3259154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of delayed leucovorin "rescue" following high-dose methotrexate in children.
    Camitta BM; Holcenberg JS
    Med Pediatr Oncol; 1978; 5(1):55-9. PubMed ID: 370536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose methotrexate for osteosarcoma: toxicity and clinical results.
    Breithaupt H; Küenzlen E
    Oncology; 1983; 40(2):85-9. PubMed ID: 6600827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
    Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
    J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient neurologic disturbances induced by high-dose methotrexate treatment.
    Jaffe N; Takaue Y; Anzai T; Robertson R
    Cancer; 1985 Sep; 56(6):1356-60. PubMed ID: 3875390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)].
    Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M
    Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.